Advanced Oncotherapy - AVO Stream Log

[link] Targets Six months: 61.90 One year: 82.93

just pulled this from Beaufort Securities's note out this morning on Research Tree... "Advanced Oncotherapy has made a significant progress in the FY2015, keeping its promises and delivered its development milestones to the timeline. In February 2016, AVO announced industrialisation agreement with Thales for LIGHT system, and further strengthened its financing through securing a £24m vendor financing agreement with Metric Capital, a pan- European private capital fund manager, to fully fund the installation of the Group’s first LIGHT machine in Harley Street. This is important news for AVO as it demonstrated not only a senior institutional lender has taken a very close look at the Group and concluded that LIGHT is viable and that its expect its first installation in Harley Street to rapidly become capable of generating strong cashflow, but also that AVO is both sufficiently confident and advanced in its planning to establish a general provision of vendor financing for its prospective international customers. In order to meet its target for the first commercial sales of LIGHT in 2017, AVO’s priorities will be to ensure the components of the LIGHT machine is compliant with the associated regulatory requirements, initial installation into the UK and to pursue commercial roll-out of the technology through existing and new partners. The Group continued to strengthen its team by appointing highly experienced senior management and shuffled the role internally to build a more commercially focussed business. As has been explained in numerous research documents, Beaufort’s commercial scenario for LIGHT is that the cost, safely, operational and size advantages its brings to the world of proton therapy, will effectively render ‘first generation’ systems all but obsolete; its development will also has potential to expand the international market for such systems from some US$2.5bn annually right now, to a figure potentially ten-times as large as LIGHT becomes the obvious successor to the similarly-priced but now relatively antiquated X-ray radiation systems that have a global installed base in excess of 20,000 units. In this respect, LIGHT uniquely faces a giant and accelerating global opportunity...."

Stockdale published a note this morning too, it's also on Research Tree.. The key financial highlight in 2015 was raising £20m net through a fund-raising at 8p per share in May. This has enabled Advanced Oncotherapy (AVO) to progress its project to have the first commercial LIGHT system deployed in Harley Street in 2017. Last week’s news of a financing agreement between AVO and Metric Capital ensures the finances are in place to complete this. We shall publish an updated research report with detailed forecasts in due course but ahead of that.

On Research Tree

Beaufort published a note this morning, you can access the full note for free... "This is significant and important news for AVO. Not only does it tell us that a senior institutional lender has taken a very close look at the Group and concluded that LIGHT is viable and that its expect its first installation in Harley Street to rapidly become capable of generating strong cash flow, but also that AVO is both sufficiently confident and advanced in its planning to establish a general provision of vendor financing for its prospective international customers. Such proton beam centre financing routes are already routinely used by first generation suppliers to provide the facilities demanded by hospitals and medical practitioners around the globe, so in this respect this is a natural step forward. Moreover, given that AVO is sticking rigidly to its development schedule, whereby the first commercial sales of LIGHT should begin in 2017 whereafter they are expected ramp up in response to significant demand, this facility is likely to become actively used. As has been explained in numerous research documents, Beaufort's commercial scenario for LIGHT is that the cost, safely, operational and size advantages its brings to the world of proton therapy, will effectively render 'first generation' systems all but obsolete; its development will also very significantly expand the international market for such systems from some US$2.5bn annually right now, to a figure potentially ten-times as large as LIGHT becomes the obvious successor to the similarly-priced but now relatively antiquated X-ray radiation systems that have a global installed base in excess of 20,000 units. In this respect, LIGHT uniquely faces a giant and accelerating global opportunity. Beaufort remains a very enthusiastic supporter of Advanced Oncotherapy and repeats..."

Read Stockdale Securities's note on ADVANCED ONCOTHERAPY PLC (AVO), out this morning on Research Tree. "We view today’s news of a financing agreement between Advanced Oncotherapy (AVO) and Metric Capital positively. The agreement will enable AVO and its partners to complete the London Proton Therapy Centre in Harley Street, the site of the first commercial LIGHT system. We shall publish an updated research report when the 2015 final results are released next month. Ahead of this and on the back of today’s significant progress we are happy to..."

At least meldrew44 is consistent. He says exactly the same on this stream as on CPX

Welcome to the new Advanced Oncotherapy stream forum! Messages posted in the Advanced Oncotherapy stream will be logged here for posterity.